Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience

Am J Hematol. 2022 Dec;97(12):E451-E453. doi: 10.1002/ajh.26728. Epub 2022 Sep 24.

Authors

Meera Mohan¹, Lisa E Rein¹, Nishanth Thalambedu², Yetunde Ogunsesan², Munawwar Hussain², Jaskirat Sethi², Fatima Khan², Sravani Gundarlapalli², Lakshmi Yarlagadda², Binod Dhakal¹, Mary Price³, Megan Shirey³, Davie Warner³, Sharmilan Thanendrarajan², Siegfried Janz¹, Sabarinath Venniyil Radhakrishnan¹, Samer Al Hadidi², Aniko Szabo¹, Anita D'Souza¹, Maurizio Zangari², Frits van Rhee², Saurabh Chhabra¹, Carolina Schinke²

Affiliations

¹ Division of Hematology/Oncology, Medical College of Wisconsin, Froedtert Clinical Cancer Center, Milwaukee, Wisconsin, USA.
² Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
³ Department of Ophthalmology, Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

PMID: 36097868
DOI: 10.1002/ajh.26728

No abstract available

Publication types

Multicenter Study
Letter
Research Support, N.I.H., Extramural

MeSH terms

Antibodies, Monoclonal, Humanized
Humans
Immunoconjugates*
Multiple Myeloma*

Substances

belantamab mafodotin
Antibodies, Monoclonal, Humanized
Immunoconjugates

Grants and funding

P20 GM109005/GM/NIGMS NIH HHS/United States